One previous study has reported that Smad7, a potential inhibitor of TGF-β/β-catenin signaling pathway, was significantly downregulated in HCC tissues.14 Consistently, our results also showed that Smad7 was a direct target of miR-92b and exhibited an inverse correlation with miR-92b expression in HCC tissues. The gene discussed is SMAD7; the disease is hepatocellular carcinoma.